Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Calprotectin in Cystic Fibrosis

  • Nisreen Rumman1, 3Email author,
  • Mutaz Sultan2, 3,
  • Khalil El-Chammas2, 5,
  • Vi Goh2, 4,
  • Nita Salzman2,
  • Diana Quintero1 and
  • Steven Werlin2
BMC Pediatrics201414:133

https://doi.org/10.1186/1471-2431-14-133

Received: 23 October 2013

Accepted: 23 May 2014

Published: 29 May 2014

Abstract

Background

There is increasing evidence that intestinal inflammation plays a major role in gastrointestinal symptoms in cystic fibrosis (CF). Fecal calprotectin is a marker that is elevated in several gastrointestinal inflammatory diseases, but little is known about its value in CF. We aimed to look for associations of elevated fecal calprotectin among CF patients and whether its level correlates with the clinical manifestations of CF.

Methods

A single stool specimen was collected from 62 patients with CF. Fecal calprotectin was measured using the commercially available ELISA kits (PhiCal test). Clinical data were collected from patients’ records and CF registry.

Results

There were no significant differences between CF patients with normal and abnormal fecal calprotectin levels. However, patients who were not receiving inhaled antibiotics had higher fecal calprotectin levels than those who were.

Conclusion

Elevated fecal calprotectin may not accurately predict intestinal inflammation in CF. However, the fact that it was elevated in both pancreatic sufficient and insufficient groups supports the concept of “cystic fibrosis enteropathy” regardless of the pancreatic status.

Background

Cystic fibrosis (CF) is the most common cause of pancreatic insufficiency (PI) in children. Between 85% - 90% of CF patients have PI and malabsorption. These patients are typically treated with pancreatic enzyme replacement therapy (PERT). However, CF patients with pancreatic sufficiency (PS), and patients with PI who receive adequate PERT, may have persistent abdominal symptoms. It has been suggested that other poorly understood non pancreatic confounding factors are likely contributors [1].

There is no specific noninvasive test to prove the presence of intestinal inflammation. Several studies have shown evidence of intestinal inflammation in CF. Increased amounts of inflammatory markers were found in whole gut lavage indicating immune activation in the intestinal mucosa of CF patients [24]. A study using wireless capsule endoscopy (WCE) showed varying degrees of inflammatory findings including edema, mucosal breaks and ulcerations in most adult patients with CF [5].

Calprotectin, a protein found mainly in neutrophils, but also in monocytes and macrophages, is released during neutrophil activation or death. Calprotectin can be measured in plasma as well as other body fluids but is six times more concentrated in feces than in blood [6, 7]. Fecal calprotectin (FC) is thus an inflammatory marker that is elevated in a variety of inflammatory intestinal diseases such as Crohn’s disease and CF [5, 7, 8]. Canani et al. showed a correlation between FC with the histologic grade of mucosal inflammation observed at endoscopy in patients with inflammatory bowel disease (IBD). In their study FC was a more accurate predictor of active mucosal inflammation than clinical scores and serum markers [8]. Similarly, Bruzesse et al. showed that intestinal mucosal inflammation is a major feature of cystic fibrosis. A comparison of 30 CF patients and 15 IBD patients with 30 healthy controls showed that the first 2 groups had significantly higher mean FC than controls [9].

The present study was performed to determine the frequency of elevated FC in CF patients, and to determine whether there are any associations with different characteristics such as pancreatic status, gastrointestinal morbidities, pulmonary function tests (PFTs) and pulmonary exacerbations. We also evaluated whether FC values differ between patients who receive certain treatments (PERT, probiotics and antibiotics) and those who do not.

Methods

Between January 2009 – November 2010 all patients attending the CF clinic at the Children’s Hospital of Wisconsin were requested to provide a stool specimen for the study at their next clinic visit regardless of their age, CF mutations, pancreatic status or severity of disease. Sixty two patients participated. The samples were stored at (−600C) until analysis. FC is stable at room temperature for up to 1 week [8, 10, 11].

Clinical data were collected from patients’ medical records and CF registry. Data collected included: age at CF diagnosis (years); age at sample collection (years); spirometry parameters including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25%-75% (FEF25-75%); gender; ethnicity; diagnosis (classic CF, or CF related metabolic syndrome - CRMS); body mass index (normal, obese, overweight); symptoms (abdominal pain, gas, vomiting, fever, pulmonary exacerbation); stool characteristics (frequency, consistency); hospitalizations; morbidities (meconium ileus, surgery, bowel resection, distal intestinal obstruction syndrome (DIOS); antibiotic use (inhaled, intravenous, oral); pancreatic enzyme supplementation; probiotic use; and pancreatic function (PI versus PS ).

Calprotectin assay

The coded stool samples were thawed, aliquots of 80–120 mg were taken and then a quantitative measurement was done using commercially available ELISA kits (PhiCal test). ELISA steps were all completed according to the instructions of the manufacturer.

This study was approved by the institutional review board of the Children’s Hospital of Wisconsin and consent and/or assent was obtained from patients and/or parents as appropriate.

Statistics

Descriptive statistics were used to summarize the sample’s characteristics. Chi square and Fisher’s exact test were used to assess demographic differences. Bivariate analysis was used to examine the effect of certain patient’s characteristics (use of inhaled, intravenous, or oral antibiotics), and FEV1 (normal being equal to or greater than 80% predicted) on FC levels. Analyses were performed for a normal FC level defined as less than 50 mcg/gm.

A statistical significance (alpha) level of 0.05 was used throughout, and SAS On Demand Enterprise Guide 4.2 (SAS Institute, Cary, NC) was used to perform all statistical analysis.

Results

A total of 62 patients participated in the study. Three were excluded because of incomplete data. Data of 59 patients (33 females, 26 males) were analyzed. Forty three patients were PI and 16 patients were PS. Fifteen patients were < 6 years of age. In our clinic patients less than 6 years of age do not routinely perform PFTs. PFTs were available for 44 patients.

Patient characteristics

The median patient age was 8 years. The median FC level was 94 mcg/gm (Table 1). There were no significant differences with respect to age at CF diagnosis, age at sample collection, and spirometry parameters between patients with normal and abnormal FC levels (Table 2). There was no statistically significant difference in FC levels between patients in regards to the other characteristics studied including gender, ethnicity, growth parameters, genotype, gastrointestinal symptoms (abdominal pain, distention/gas, vomiting, and stool pattern), being on PERT and/or probiotics, history of meconium ileus, bowel surgery/resection, history of distal intestinal obstruction syndrome (DIOS), number of pulmonary exacerbations and hospitalizations (Table 3). However, there was a significant statistical difference in regards to the use of inhaled antibiotics; those who were not on inhaled antibiotics had higher odds of having abnormal FC levels higher than 50 mcg/gm (p value 0.0101) (Table 4).
Table 1

Study population

Factors

N

Median (range)

Fecal calprotectin (mcg/gm)

59

94.29 (10–200)

Age at sample collection (yrs)

59

0.67 (0.04-4.58)

Age at diagnosis (yrs)

59

0 (0–2.17)

FVC (%)

44

100 (53–147)

FEV1 (%)

44

93.5 (25–139)

FEF25 (%)

44

85 (6–170)

Table 2

Pulmonary function test characteristics

Factors

Normal

Abnormal

P-value

 

N

Median

N

Median

 

Age at diagnosis (yrs)

18

0.04

41

0

0.9718

Age at sample (yrs)

18

6.00

41

9.00

0.1956

FVC (%)

15

105.00

29

99.00

0.3040

FEV1 (%)

15

106.00

29

92.00

0.3040

FEF25 (%)

15

92.00

29

84.00

0.5858

Table 3

Patient characteristics

Factors

N

Normal FC (%)

Abnormal FC (%)

P-value

Gender

   

1.0000

Female

33

30

70

 

Male

26

31

69

 

Ethnicity

   

0.3778

American Indian

1

100

0

 

Black

2

0

100

 

White

50

32

68

 

Hispanic

2

50

50

 

Mixed

1

0

100

 

Other

3

0

100

 

Diagnosis

   

0.6639

Classic CF (PI and PS)

52

29

71

 

CRMS

7

43

57

 

Symptoms

    

Abdominal pain

   

1.0000

No

51

31

67

 

Yes

8

25

75

 

Gas

   

0.2181

No

56

29

71

 

Yes

3

67

33

 

Vomiting

   

0.3027

No

55

33

67

 

Yes

4

0

100

 

Fever

    

No

59

31

69

 

Yes

0

0

0

 

Exacerbation

   

0.7748

No

37

32

68

 

Yes

22

27

78

 

Stool frequency

   

0.6274

1

16

31

69

 

1 or 2

7

14

86

 

1 or 3

1

0

100

 

2

17

24

76

 

2 or 3

5

40

60

 

2 or 4

1

100

0

 

3

4

25

75

 

3 or 4

4

50

50

 

4

2

50

50

 

5 or 6

1

100

0

 

7 or 8

1

0

100

 

Stool description

   

0.6394

Formed

47

32

68

 

Formed foul

1

0

100

 

Formed greasy

1

0

100

 

Foul greasy

1

100

0

 

Loose

5

40

60

 

Loose formed

2

0

100

 

Loose foul

1

0

100

 

Soft

1

0

100

 

Hospitalization

   

0.7187

0

33

27

73

 

1

9

33

67

 

2

5

20

80

 

3

7

57

43

 

4

3

33

67

 

7

1

0

100

 

10

1

0

100

 

Meconium Ileus

   

0.7659

No

40

33

68

 

Yes

19

26

74

 

Surgery

   

1.0000

No

40

30

70

 

Yes

19

32

68

 

Intestinal resection

   

1.0000

No

51

31

69

 

Yes

8

25

75

 

Distal intestinal obstruction syndrome

   

1.0000

No

58

31

70

 

Yes

1

0

100

 

Inhaled antibiotics

   

0.0101

No

35

17

83

 

Yes

24

50

50

 

IV antibiotics

   

0.1604

No

54

28

72

 

Yes

5

60

40

 

Oral antibiotics

   

0.0880

No

31

19

81

 

Yes

28

43

57

 

Pancreatic enzyme

   

0.7533

No

16

25

75

 

Yes

43

33

67

 

Probiotic

   

0.0894

No

57

28

72

 

Yes

2

100

0

 

Pancreatic status

   

0.3433

Insufficient

43

35

65

 

Sufficient

16

19

81

 
Table 4

Bivariate analysis of antibiotic use and fecal calprotectin (using normal cut off for fecal calprotectin of <50 Mcg/Gm)

  

%

OR

95% CI

P-value

Inhaled

    

0.0101

 

Normal

67

R

  
 

Abnormal

29

0.21

0.06, 0.68

 

IV

    

0.1604

 

Normal

17

R

  
 

Abnormal

5

0.26

0.04, 1.69

 

Oral

    

0.0880

 

Normal

67

R

  
 

Abnormal

39

0.32

0.1, 1.02

 

Bivariate analysis

Results of the bivariate analysis are summarized in Tables 4 and 5. The only significant finding was that patients with a normal FC level compared to those with levels above 50 mcg/gm, had higher odds of being on antibiotics (inhaled, intravenous, or oral).
Table 5

Bivariate analysis of FEV1 and fecal calprotectin (using normal cut off for fecal Calprotectin of <50 mcg/gm)

 

%

OR

95% CI

p-value

FEV1

    

0.4884

 

Normal

20

R

  

Abnormal

34

2.11

0.48, 9.24

Discussion

The evidence that factors other than PI and malabsorption play a role in “CF enteropathy” is increasing [2, 5, 9, 12, 13]. Intestinal inflammation may be one of the factors that result in persistence of GI symptoms even in the patients who are PS or PI patients receiving adequate PERT.

In the CF lung, there is still controversy whether inflammation precedes or follows infection. While Armstrong et al. found that inflammation follows respiratory infections [14, 15], other studies of broncho-alveolar lavage fluid in infants with CF found elevated inflammatory markers early in the course of the disease even in the absence of bacterial colonization or infection [16, 17]. This suggests that inflammation might be the earliest event in the CF lung causing damage and thus predisposing to infection, and that the basic defect in cystic fibrosis transmembrane regulator (CFTR) itself may initiate or amplify inflammation.

As with the lungs, the CFTR expression is high in the intestines. Dysregulation of the inflammatory response is thought to be present in tissues that express CFTR [2]. This could explain why PERT treatment does not completely correct gastrointestinal symptoms and why patients with PS may still have gastrointestinal symptoms. Bruzzese et al. showed that probiotics reduce intestinal inflammation and decrease pulmonary exacerbations and hospital admissions in patients with CF, this indicates that there may be a relationship between pulmonary and intestinal inflammation in CF [18].

Intestinal inflammation is a typical feature in CF [13]. This may be related to several other factors in addition to a dysregulated inflammatory response associated with the basic cellular defect of CFTR [2]. High doses of PERT can cause inflammation and fibrosing colonopathy [19]. Multiple factors predispose CF patients to small intestinal bacterial overgrowth (SIBO) which can cause inflammation, mucosal damage and maldigestion [1, 18]. A local intestinal mucosal defect, believed to be present in CF patients, may explain the increased permeability to sugars and the disacchariduria that characterizes CF patients [20].

The gold standard for the detection of intestinal mucosal inflammation is endoscopy and biopsy, which are invasive and expensive. There is no other specific noninvasive test to accurately detect intestinal inflammation. But, based on previous studies correlating FC levels with the severity of inflammation in other inflammatory conditions, mainly inflammatory bowel disease (IBD), we looked for evidence of intestinal inflammation in CF patients by measuring FC [8, 10, 11].

FC in CF has been previously evaluated in 2 studies. Bruzzese et al. found that FC was elevated in 27 of 30 pediatric CF patients [9]. In 10 patients FC normalized after treatment with a probiotic, lactobacillus GG (LGG), suggesting the possibility of bacterial overgrowth. In the same study rectal nitric oxide (NO) production, another non invasive marker of intestinal inflammation that is elevated in the stool of children with active IBD was increased, thus supporting the FC results. NO production also decreased after LGG [9]. In the second study, FC was measured along with wireless capsule endoscopy (WCE) to quantify and localize intestinal inflammation in patients with CF and relate these findings to the clinical status and pancreatic phenotype [5]. The images showed generalized enteropathy unrelated to pancreatic function status. FC was measured in 30 patients. It was normal (<50 mcg/gm) in all 9 PS patients as well as in all patients in the control group, but elevated in 18/21 of the PI patients indicating intestinal inflammation only in the patients with PI [5].

We decided to identify the role of calprotectin in our CF population. In contrast to the described studies, we found that 10/16 PS patients had elevated FC levels comparable to those of PI patients. Since FC is a measure of inflammation, this indicates that intestinal inflammation is also present in PS patients and implies that inflammation is part of the disease process in CF regardless of the pancreatic status and is not related to PERT. In the present study there was no correlation between FC and any of the characteristics studied nor was there a difference in FC levels between PI and PS patients. Only 19 patients in our study (6/16 PS and 13/43 PI) had levels < 50 mcg/gm. This finding supports the concept of “CF enteropathy” as an independent entity in the disease process.

Pulmonary function tests were available for 44 patients. Patients with lower FEV1 were more likely to have higher FC levels; however this was not statistically significant. Lower FEV1 indicates worse pulmonary status, and hence probably more sputum production which if swallowed could contribute to increased intestinal inflammation. Excluding the sputum from the GI tract is impossible since the muco-ciliary escalator cannot be turned off in vivo [2, 12]. Bacteria and other contents of swallowed sputum might be involved in direct stimulation of the intestinal mucosa. Calprotectin in the sputum itself might also increase the fecal levels. Golden et al. studied plasma calprotectin levels as a marker of pulmonary inflammation in CF. They found that plasma calprotectin was significantly higher in CF patients compared to matched controls [21]. Both sputum and serum calprotectin significantly decreased following treatment of a pulmonary exacerbation in a study by Gray et al. [22]. In our study, there was no significant difference in FC levels between patients who had a pulmonary exacerbation within one month prior to sample collection and those who had no recent exacerbations. The patients who were receiving inhaled antibiotics had significantly lower FC levels. But this was not true for oral or intravenous antibiotic usage (within one month prior to sample collection).

An altered intestinal microbiome may be a stimulus for inflammation and thus elevated FC levels. CF patients have multiple risk factors for small intestinal bacterial overgrowth (SIBO) including inspissated intestinal secretions, constipation, slow intestinal motility and frequent courses of antibiotics [23]. The frequent use of acid blockers, particularly proton pump inhibitors, in CF patients is another trigger for SIBO [23]. Lisowska et al. studied evidence of SIBO in 25 CF patients using the hydrogen-methane breath test, and at the same time measured the FC levels in those patients [24]. They found similar FC levels in both SIBO positive and negative patients, concluding that SIBO does not correlate with intestinal inflammation in CF. We did not assess our patients for SIBO.

We are aware that our study had several limitations: It is a small study at only one CF center, there was no control group and only one sample was obtained. Larger multicenter prospective studies may help determine if serial and longitudinal calprotectin levels may have clinical relevance during symptomatic episodes and whether certain interventions will have an impact on these levels. However, the finding of abnormal calprotectin levels in the pediatric population brings up the question about early detection of CF enteropathy. In addition, our observation of lower levels of calprotectin in individuals on inhaled steroids may prove that bacterial control in the intestinal tract may be also beneficial.

Conclusion

There is increasing evidence that intestinal inflammation is part of the disease in CF patients. The causes of this inflammation may be multifactorial, and could be contributing to the gastrointestinal symptoms in PS patients and PI patients receiving apparently adequate PERT. FC is used as a marker of inflammation and although it may not be as an accurate indicator of intestinal inflammation in CF as it is in other inflammatory conditions of the intestines the fact that it was elevated in both PS and PI groups supports the concept of “CF enteropathy” regardless of the pancreatic status. This study highlights the limitation of an increasingly popular test as a marker of intestinal inflammation in the CF population. However, a larger cohort of patients is needed to confirm these findings.

Declarations

Acknowledgements

The authors would like to acknowledge Mary Ellen Freeman and Tami Miller for their help in collecting consents from patients, and receiving the samples. Without them this work could not have been done.

Authors’ Affiliations

(1)
Department of Pediatrics, Divisions of Pulmonary and Sleep Medicine, The Medical College of Wisconsin
(2)
Gastroenterology, The Children’s Hospital of Wisconsin
(3)
Department of Pediatrics, Makassed Hospital
(4)
Boston Medical Center One Boston Medical Center
(5)
Mercy Children’s Hospital and Clinics

References

  1. Borowitz D, Durie PR, Clarke LL, Werlin SL, Taylor CJ, Semler J, De Lisle RC, Lewindon P, Lichtman SM, Sinaasappel M, Baker RD, Baker SS, Verkade HJ, Lowe ME, Stallings VA, Janghorbani M, Butler R, Heubi J: Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2005, 41 (3): 273-285. 10.1097/01.mpg.0000178439.64675.8d.View ArticlePubMedGoogle Scholar
  2. Smyth RL, Croft NM, O'Hea U, Marshall TG, Ferguson A: Intestinal inflammation in cystic fibrosis. Arch Dis Child. 2000, 82 (5): 394-399. 10.1136/adc.82.5.394.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Croft NM, Marshall TG, Ferguson A: Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet. 1995, 346 (8985): 1265-1267. 10.1016/S0140-6736(95)91864-7.View ArticlePubMedGoogle Scholar
  4. Croft NM, Marshall TG, Ferguson A: Direct assessment of gastrointestinal inflammation and mucosal immunity in children with cystic fibrosis. Postgrad Med J. 1996, 72 (Suppl 2): S32-S36.PubMedGoogle Scholar
  5. Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M: Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010, 51 (3): 304-308.PubMedGoogle Scholar
  6. Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y: Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007, 45 (4): 414-420. 10.1097/MPG.0b013e31810e75a9.View ArticlePubMedGoogle Scholar
  7. Summerton CB, Longlands MG, Wiener K, Shreeve DR: Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002, 14 (8): 841-845. 10.1097/00042737-200208000-00005.View ArticlePubMedGoogle Scholar
  8. Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R: Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008, 40 (7): 547-553. 10.1016/j.dld.2008.01.017.View ArticlePubMedGoogle Scholar
  9. Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, Guarino A: Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004, 20 (7): 813-819. 10.1111/j.1365-2036.2004.02174.x.View ArticlePubMedGoogle Scholar
  10. Bunn SK, Michael Bisset W, Main MJC, Gray ES, Olson S, Golden BE: Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001, 33 (1): 14-22. 10.1097/00005176-200107000-00003.View ArticlePubMedGoogle Scholar
  11. Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, Cirillo P, Paparo F, Troncone R: Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004, 36 (7): 467-470. 10.1016/j.dld.2004.02.009.View ArticlePubMedGoogle Scholar
  12. Briars G: Intestinal inflammation in cystic fibrosis. Arch Dis Child. 2001, 84 (4): 374-375.View ArticlePubMedGoogle Scholar
  13. Raia V, Maiuri L, De Ritis G, De Vizia B, Vacca L, Conte R, Auricchio S, Londei M: Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res. 2000, 47 (3): 344-350. 10.1203/00006450-200003000-00010.View ArticlePubMedGoogle Scholar
  14. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD: Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997, 156 (4 Pt 1): 1197-1204.View ArticlePubMedGoogle Scholar
  15. Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin JB, Robertson CF, Grimwood K: Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005, 40 (6): 500-510. 10.1002/ppul.20294.View ArticlePubMedGoogle Scholar
  16. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R: The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995, 20 (2): 63-70. 10.1002/ppul.1950200203.View ArticlePubMedGoogle Scholar
  17. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995, 151 (4): 1075-1082.PubMedGoogle Scholar
  18. Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, Maiuri L, Guarino A: Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr. 2007, 26 (3): 322-328. 10.1016/j.clnu.2007.01.004.View ArticlePubMedGoogle Scholar
  19. FitzSimmons SC, Burkhart GA, Borowitz MD, Grand RJ, Hammerstrom T, Durie PR, Lloyd-Still JD, Lowenfels AB: High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997, 336 (18): 1283-1289. 10.1056/NEJM199705013361803.View ArticlePubMedGoogle Scholar
  20. Leclercq-Foucart J, Forget PP, van Cutsem JL: Lactulose-rhamnose intestinal permeability in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1987, 6 (1): 66-70. 10.1097/00005176-198701000-00012.View ArticlePubMedGoogle Scholar
  21. Golden BE, Clohessy PA, Russell G, Fagerhol MK: Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child. 1996, 74 (2): 136-139. 10.1136/adc.74.2.136.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP: Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010, 9 (3): 193-198. 10.1016/j.jcf.2010.01.005.View ArticlePubMedGoogle Scholar
  23. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K: Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007, 44 (2): 212-218. 10.1097/MPG.0b013e31802c0ceb.View ArticlePubMedGoogle Scholar
  24. Lisowska A, Madry E, Pogorzelski A, Szydlowski J, Radzikowski A, Walkowiak J: Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand J Clin Lab Invest. 2010, 70 (5): 322-326. 10.3109/00365513.2010.486869.View ArticlePubMedGoogle Scholar
  25. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2431/14/133/prepub

Copyright

© Rumman et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.